Phaseline

Companies › Sovargen

Sovargen: clinical trials, targets and expected readouts

1 active drug program in 8 registered trials: 4 Phase 1, 4 Phase 2; Oncology, Other; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Paxalisib (SVG103)
PI3-kinase class I inhibitor
PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2Phase 1Focal Cortical Dysplasia; Primary Central Nervous System Lymphoma; Glioblastoma; CDK Gene Mutation …Feb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04906096Paxalisib (SVG103)Phase 2Primary Central Nervous System LymphomaOncologyDec 2026
NCT04192981Paxalisib (SVG103)Phase 1Brain MetastasesOncologyDec 2026
NCT07287202Paxalisib (SVG103)Phase 1Focal Cortical DysplasiaOtherFeb 2027
NCT03970447Paxalisib (SVG103)Phase 2GlioblastomaOncologyJun 2028
NCT03994796Paxalisib (SVG103)Phase 2CDK Gene MutationOncologyJun 2028
NCT07391215Paxalisib (SVG103)Phase 1Malignant Primary GliomasOncologyJan 2029
NCT06208657Paxalisib (SVG103)Phase 1Childhood CancerOncologyDec 2030
NCT07447076Paxalisib (SVG103)Phase 2Recurrent Atypical Teratoid/Rhabdoid TumorOncologyDec 2035

Targets

PIK3R1 (1) PIK3CB (1) PIK3CG (1) PIK3CA (1) PIK3R2 (1)

Companies with the same targets

Eli Lilly Restorbio Celcuity ThromBio Rhizen Pharmaceuticals SecuraBio Stelexis BioSciences Novartis Recursion Pharmaceuticals TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.